- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04671368
Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology
A Multi-center, Prospective, Self-Controlled Diagnostic Accuracy Comparative Studies of Artificial Intelligence Diagnostic System for Surgical Neuropathology
Aperçu de l'étude
Statut
Les conditions
Description détaillée
In this study, 141 patients will be recruited. After being enrolled, the patients will accept surgery and specimens for pathological analysis will be taken according to the routine treatment process.
The histopathologic slides will then be digitized by a whole-slide scanner. The images will be reviewed by gold standard committee for evaluation of ground truth. And then be separately diagnosed by Artificial Intelligence Diagnostic System and practicing pathologists. So the investigators can compare the diagnostic efficiency of Artificial Intelligence with that of pathologists, thus understand the gap between artificial intelligence and actual clinical practice.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients or their guardians understand the research process, agree to use their data, and sign the informed consent form;
- Aged >=18 years;
- MRI shows intracranial spaceoccupying lesions;
- The clinical diagnosis is glioma, metastasis or lymphoma thus requiring surgical treatment;
- The patient is willing to accept the surgery.
Exclusion Criteria:
- The patient has serious underlying diseases thus is not suitable for surgery;
- After further clinical evaluation, surgical treatment was not the best choice;
- The patient participate in clinical research of other drugs or devices;
- The researchers believe that there are other factors that will make the patients unable to complete the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Artificial Intelligence
A deep learning based artificial intelligence diagnostic system(DOI:10.1093/neuonc/noaa163)
|
The investigators will use the Artificial Intelligence Diagnostic System to review the H&E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
|
|
Comparateur actif: Practicing Pathologists
One pathologist who has at least 5 years of experience
|
The ordinary pathologist will review the H&E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
|
|
Autre: Gold Standard
A committee composed of two expert pathologists who has at least 10 years of experience and one expert pathologist who has at least 15 years of experience
|
Firstly, the two expert pathologist(>=10 years of experience) will review the H&E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnostic Accuracy of Study Arms
Délai: 1 week after the last patient's diagnosis is completed
|
The number of correctly diagnosed participants by study arms divided by the total number of participants
|
1 week after the last patient's diagnosis is completed
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sensitivity and specificity of Study Arms
Délai: 1 week after the last patient's diagnosis is completed
|
Sensitivity and specificity of study arms for each type calculated by 2x2 tables
|
1 week after the last patient's diagnosis is completed
|
|
Spearman Coefficient of Study Arms related to Gold Standard
Délai: 1 week after the last patient's diagnosis is completed
|
Spearman Correlation Analysis between Study Arms and Gold Standard
|
1 week after the last patient's diagnosis is completed
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Cuiyun Wu, Ph.D, Huashan Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PAAI2020
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .